GLP-1 drugs have revolutionized the way we treat Type 2 diabetes and obesity
One of the most important clinical guidelines I give my patients is this: Use CJC-1295 or Tesamorelin for 6090 days, then take a 30-day break before beginning another cycle
The mechanistic interpretation, debated for two decades, was that GIPR agonism did two things: it contributed to appetite suppression and energy expenditure in addition to GLP-1R activation, and - separately - it appeared to improve tolerability by reducing GLP-1-mediated nausea and GI adverse events
Approximately 25% of total weight lost on tirzepatide was lean mass (SURMOUNT-1 DXA substudy), and in semaglutide trials, that proportion may reach up to 40% (STEP 1 DXA subset)
11 Studies have shown that plasma/serum malondialdehyde (MDA), a marker of polyunsaturated fatty acids peroxidation, and inflammatory marker like C-reactive protein (CRP) are significantly elevated in GDM